PARDES BIOSCIENCES, INC.

[WEB-INTEL 2026-08-26] 6 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share" [https://leadiq.com/c/pardes-biosciences/5ecbaeda8a998f161e2052af] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The shareholders of FSII approved the transaction on December 23, 2021." [https://firstwordpharma.com/story/5468975] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The combined company commenced trading its shares Monday, December 27 on the Nasdaq Global Market" [https://www.whitecase.com/news/press-release/white-case-advises-fs-development-corp-ii-business-combination-pardes] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised a total of $51.6M from 1 Series C round on Feb 03, 2021." [https://tracxn.com/d/companies/pardes-biosciences/__lA01_u-DwrjC3LwQzKbJoUsQNU8neDt4XR6_vXHDLqc/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes said it raised $52 million before its listing in a single funding round in January 2021 from Foresite, venture-capital firm Khosla" [https://www.wsj.com/articles/covid-19-pill-developer-to-spend-spac-ipo-funds-on-clinical-trial-hiring-11641983403] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The raise brought in about $274 million. Prior to the IPO, it had raised $52 million in a single funding round in January 2021." [https://www.biospace.com/pardes-bio-to-use-ipo-funds-to-trial-covid-19-drug] [WEB-INTEL 2026-08-27] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised a total of $51.6M from 1 Series C round on Feb 03, 2021." [https://tracxn.com/d/companies/pardes-biosciences/__lA01_u-DwrjC3LwQzKbJoUsQNU8neDt4XR6_vXHDLqc/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised $276M in total disclosed funding. The most recent round on record is a IPO round of $276M in June 2021." [https://startupfundraising.com/companies/pardes-biosciences] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In January 2021, Pardes Biosciences, Inc. raised USD 51.61 million in Venture funding from the investors Foresite Capital, GMF Capital Partners, and Khosla Ventures." [https://www.preqin.com/data/profile/asset/pardes-biosciences-inc-/464285] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes said it raised $52 million before its listing in a single funding round in January 2021 from Foresite, venture-capital firm Khosla" [https://www.wsj.com/articles/covid-19-pill-developer-to-spend-spac-ipo-funds-on-clinical-trial-hiring-11641983403] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The raise brought in about $274 million. Prior to the IPO, it had raised $52 million in a single funding round in January 2021." [https://www.biospace.com/pardes-bio-to-use-ipo-funds-to-trial-covid-19-drug] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The shareholders of FSII approved the transaction on December 23, 2021." [https://firstwordpharma.com/story/5468975] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The combined company, which is renamed Pardes Biosciences, Inc., commenced trading its shares Monday, December 27 on the Nasdaq Global Market" [https://www.whitecase.com/news/press-release/white-case-advises-fs-development-corp-ii-business-combination-pardes] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company's net cash at closi" [https://leadiq.com/c/pardes-biosciences/5ecbaeda8a998f161e2052af] [WEB-INTEL 2026-08-27] 9 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised $276M in total disclosed funding. The most recent round on record is a IPO round of $276M in June 2021." [https://startupfundraising.com/companies/pardes-biosciences] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In January 2021, Pardes Biosciences, Inc. raised USD 51. 61 million in Venture funding from the investors Foresite Capital, GMF Capital Partners, and Khosla" [https://www.preqin.com/data/profile/asset/pardes-biosciences-inc-/464285] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised a total of $51.6M from 1 Series C round on Feb 03, 2021." [https://tracxn.com/d/companies/pardes-biosciences/__lA01_u-DwrjC3LwQzKbJoUsQNU8neDt4XR6_vXHDLqc/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes said it raised $52 million before its listing in a single funding round in January 2021 from Foresite, venture-capital firm Khosla" [https://www.wsj.com/articles/covid-19-pill-developer-to-spend-spac-ipo-funds-on-clinical-trial-hiring-11641983403] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The raise brought in about $274 million." [https://www.biospace.com/pardes-bio-to-use-ipo-funds-to-trial-covid-19-drug] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Prior to the IPO, it had raised $52 million in a single funding round in January 2021." [https://www.biospace.com/pardes-bio-to-use-ipo-funds-to-trial-covid-19-drug] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The shareholders of FSII approved the transaction on December 23, 2021." [https://firstwordpharma.com/story/5468975] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The combined company, which is renamed Pardes Biosciences, Inc., commenced trading its shares Monday, December 27 on the Nasdaq Global Market" [https://www.whitecase.com/news/press-release/white-case-advises-fs-development-corp-ii-business-combination-pardes] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share" [https://leadiq.com/c/pardes-biosciences/5ecbaeda8a998f161e2052af] [WEB-INTEL 2026-08-27] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised $276M in total disclosed funding. The most recent round on record is a IPO round of $276M in June 2021." [https://startupfundraising.com/companies/pardes-biosciences] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In January 2021, Pardes Biosciences, Inc. raised USD 51. 61 million in Venture funding from the investors Foresite Capit [WEB-INTEL 2026-09-02] 8 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised a total of $51.6M from 1 Series C round on Feb 03, 2021." [https://tracxn.com/d/companies/pardes-biosciences/__lA01_u-DwrjC3LwQzKbJoUsQNU8neDt4XR6_vXHDLqc/funding-and-investors] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In January 2021, Pardes Biosciences, Inc. raised USD 51. 61 million in Venture funding from the investors Foresite Capital, GMF Capital Partners, and Khosla" [https://www.preqin.com/data/profile/asset/pardes-biosciences-inc-/464285] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes Biosciences has raised $276M in total disclosed funding. The most recent round on record is a IPO round of $276M in June 2021." [https://startupfundraising.com/companies/pardes-biosciences] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Pardes said it raised $52 million before its listing in a single funding round in January 2021 from Foresite, venture-capital firm Khosla" [https://www.wsj.com/articles/covid-19-pill-developer-to-spend-spac-ipo-funds-on-clinical-trial-hiring-11641983403] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The raise brought in about $274 million. Prior to the IPO, it had raised $52 million in a single funding round in January 2021." [https://www.biospace.com/pardes-bio-to-use-ipo-funds-to-trial-covid-19-drug] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The shareholders of FSII approved the transaction on December 23, 2021." [https://firstwordpharma.com/story/5468975] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The combined company, which is renamed Pardes Biosciences, Inc., commenced trading its shares Monday, December 27 on the Nasdaq Global Market" [https://www.whitecase.com/news/press-release/white-case-advises-fs-development-corp-ii-business-combination-pardes] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "MediPacific will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company's net cash at closi" [https://leadiq.com/c/pardes-biosciences/5ecbaeda8a998f161e2052af]